Acadian Asset Management LLC Has $15.09 Million Holdings in Baxter International Inc (BAX)

Acadian Asset Management LLC reduced its position in Baxter International Inc (NYSE:BAX) by 14.6% in the first quarter, Holdings Channel reports. The institutional investor owned 185,612 shares of the medical instruments supplier’s stock after selling 31,818 shares during the period. Acadian Asset Management LLC’s holdings in Baxter International were worth $15,092,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Horrell Capital Management Inc. raised its stake in shares of Baxter International by 0.4% in the 1st quarter. Horrell Capital Management Inc. now owns 31,167 shares of the medical instruments supplier’s stock valued at $2,534,000 after purchasing an additional 138 shares in the last quarter. Berman Capital Advisors LLC raised its stake in shares of Baxter International by 8.5% in the 1st quarter. Berman Capital Advisors LLC now owns 1,793 shares of the medical instruments supplier’s stock valued at $145,000 after purchasing an additional 141 shares in the last quarter. Brookmont Capital Management raised its stake in shares of Baxter International by 3.7% in the 4th quarter. Brookmont Capital Management now owns 4,048 shares of the medical instruments supplier’s stock valued at $266,000 after purchasing an additional 146 shares in the last quarter. Parsons Capital Management Inc. RI raised its stake in shares of Baxter International by 0.4% in the 1st quarter. Parsons Capital Management Inc. RI now owns 33,782 shares of the medical instruments supplier’s stock valued at $2,747,000 after purchasing an additional 146 shares in the last quarter. Finally, Sullivan Bruyette Speros & Blaney LLC raised its stake in shares of Baxter International by 3.6% in the 4th quarter. Sullivan Bruyette Speros & Blaney LLC now owns 4,322 shares of the medical instruments supplier’s stock valued at $284,000 after purchasing an additional 150 shares in the last quarter. 84.39% of the stock is owned by institutional investors.

In other Baxter International news, SVP Giuseppe Accogli sold 38,297 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $76.78, for a total value of $2,940,443.66. Following the sale, the senior vice president now owns 70,001 shares in the company, valued at $5,374,676.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Thomas T. Stallkamp sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $75.16, for a total transaction of $75,160.00. Following the completion of the sale, the director now owns 6,780 shares in the company, valued at approximately $509,584.80. The disclosure for this sale can be found here. Insiders sold 5,057,187 shares of company stock worth $386,297,619 in the last 90 days. 0.70% of the stock is owned by company insiders.

A number of equities research analysts have recently issued reports on BAX shares. Zacks Investment Research lowered shares of Baxter International from a “buy” rating to a “hold” rating in a research note on Tuesday, April 2nd. Morgan Stanley upped their target price on shares of Baxter International from $80.00 to $83.00 and gave the company an “overweight” rating in a research note on Tuesday, March 5th. Piper Jaffray Companies restated an “overweight” rating and issued a $80.00 target price on shares of Baxter International in a research note on Friday, February 1st. Barclays upped their target price on shares of Baxter International from $72.00 to $75.00 and gave the company an “equal weight” rating in a research note on Monday, April 15th. Finally, Cowen set a $75.00 target price on shares of Baxter International and gave the company a “hold” rating in a research note on Monday, April 22nd. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Baxter International has a consensus rating of “Buy” and an average price target of $78.33.

BAX opened at $75.10 on Monday. The stock has a market cap of $38.31 billion, a P/E ratio of 24.62, a price-to-earnings-growth ratio of 1.77 and a beta of 0.96. Baxter International Inc has a fifty-two week low of $61.05 and a fifty-two week high of $82.25. The company has a current ratio of 1.83, a quick ratio of 1.30 and a debt-to-equity ratio of 0.50.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, April 25th. The medical instruments supplier reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.08. The firm had revenue of $2.63 billion for the quarter, compared to analyst estimates of $2.61 billion. Baxter International had a net margin of 14.27% and a return on equity of 20.04%. Baxter International’s quarterly revenue was down 1.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.70 earnings per share. Sell-side analysts predict that Baxter International Inc will post 3.32 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 1st. Investors of record on Friday, June 7th will be paid a dividend of $0.22 per share. This is a positive change from Baxter International’s previous quarterly dividend of $0.19. The ex-dividend date is Thursday, June 6th. This represents a $0.88 annualized dividend and a yield of 1.17%. Baxter International’s dividend payout ratio is 24.92%.

COPYRIGHT VIOLATION WARNING: This article was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/05/27/acadian-asset-management-llc-has-15-09-million-holdings-in-baxter-international-inc-bax.html.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Featured Article: What are catch-up contributions?

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.